OncoMatch/Clinical Trials/NCT06994195
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer
Is NCT06994195 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including BL-B01D1 and Liposomal doxorubicin, Paclitaxel or Topotecan for epithelial ovarian cancer.
Treatment: BL-B01D1 · Liposomal doxorubicin, Paclitaxel or Topotecan — This trial is a registered, phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with platinum-resistant recurrent epithelial ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Allowed: FOLR1 positivity
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Previously treated with a platinum-based regimen and confirmed to have platinum-resistant recurrence
Cannot have received: antibody-drug conjugate targeting topoisomerase I inhibitors
Exception: front line only
Front line received ADCs targeting topoisomerase I inhibitors
Cannot have received: EGFR inhibitor
Exception: front line only
Front line received ADCs targeting EGFR
Cannot have received: HER3 inhibitor
Exception: front line only
Front line received ADCs targeting HER3
Cannot have received: autologous or allogeneic stem cell transplant
Had a history of autologous or allogeneic stem cell transplantation
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
no severe cardiac dysfunction, with left ventricular ejection fraction ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify